The leading Indian pathology chain, iGenetic Diagnostics, has entered into a strategic collaboration with Lucence Diagnostics, a genomic medicine company headquartered in Singapore, to make its liquid biopsy tests for early cancer detection and treatment available in India.
Through this collaboration, iGenetic Diagnostics will be making Lucence’s liquid biopsy test – LiquidHALLMARK available to the masses. LiquidHALLMARK is the world’s first blood test to span multiple cancer-causing mutations and viruses.
This test improves cancer diagnosis and treatment selection for patients with advanced cancer. The blood test analyses the cancer-driving mutations from the DNA shed by the tumor into the bloodstream to determine the best available treatment, which include targeted therapy and immunotherapy.
“Delivering advanced molecular diagnostics that can enable a quick and precise diagnosis will help to save lives. We are excited to collaborate with Lucence to deliver their proprietaryliquid biopsy tests for early cancer detection and better treatment selection to patients in India. Lucence’s technology will help doctors personalize treatment for their patients and improve patient outcomes,’’said Arunima Patel, CEO and Managing Director, iGenetic Diagnostics.
iGenetic specialises in providing the full spectrum of pathology solutions including molecular diagnostic services that deliver quicker and accurate results for its customers. The company is headquartered in Mumbai with seven processing labs and over 20 collection centres across India. The new blood test will further strengthen iGenetic Diagnostics’ offerings in India.
LiquidHALLMARK targets a wide range of cancers, especially the cancer types that are most prevalent in Asia, like lung, colon and breast cancers.
“Lucence is delighted to collaborate with iGenetic to launch our liquid biopsy tests in India. We are focused on reducing avoidable cancer deaths, particularly in Asia, where more than 4 million cancer deaths occur annually. With iGenetic’s experience and presence in India, we are confident that this partnership will drive better cancer care in the country,’’said Dr Min-Han Tan, Founder and CEO, Lucence Diagnostics.